Abstract:Over 50% of patients who take statins are still at risk of developing atherosclerotic cardiovascular disease (ASCVD) and do not achieve their goal LDL-C levels. This residual risk is largely dependent on triglyceride-rich lipoproteins (TRL) and their remnants. In essence, remnant cholesterol-rich chylomicron (CM) and very-low-density lipoprotein (VLDL) particles play a role in atherogenesis. These remnants increase when lipoprotein lipase (LPL) activity is inhibited. ApoCIII has been thoroughly studied as a chief inhibitor and therapeutic options to curb its effect are available. On top of apoCIII regulation of LPL activity, there is a more precise control of LPL in various tissues, which makes it easier to physiologically divide the TRL burden according to the body's requirements. In general, oxidative tissues such as skeletal and cardiac muscle preferentially take up lipids during fasting. Conversely, LPL activity in adipocytes increases significantly after feeding, while its activity in oxidative tissues decreases concurrently. This perspective addresses the recent improvements in our understanding of circadian LPL regulations and their therapeutic implications. Three major tissue-specific lipolysis regulators have been identified: ANGPTL3, ANGPTL4, and ANGPTL8. Briefly, during the postprandial phase, liver ANGPTL8 acts on ANGPTL3 (which is released continuously from the liver) to inhibit LPL in the heart and muscle through an endocrine mechanism. On the other hand, when fasting, ANGPTL4, which is released by adipocytes, inhibits lipoprotein lipase in adipose tissue in a paracrine manner. ANGPTL3 inhibitors may play a therapeutic role in the treatment of hypertriglyceridemia. Several approaches are under development. We look forward to future studies to clarify (a) the nature of hormonal and nutritional factors that determine ANGPTL3, 4, and 8 activities, along with what long-term impacts may be expected if their regulation is impaired pharmacologically; (b) the understanding of the quantitative hierarchy and interaction of the regulatory actions of apoCIII, apoAV, and ANGPTL on LPL activity; (c) strategies for the safe and proper treatment of postprandial lipemia; and (d) the effect of fructose restriction on ANGPTL3, ANGPTL4, and ANGPTL8.

Lipoprotein Lipase Transporter GPIHBP1 and Triglyceride-Rich Lipoprotein Metabolism

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

The GPIHBP1-LPL Complex and Its Role in Plasma Triglyceride Metabolism: Insights into Chylomicronemia.

New Insights in GPIHBP1 and the Intravascular Processing of Triglyceride-rich Lipoproteins

Triglyceride Metabolism and Angiopoietin-Like Proteins in Lipoprotein Lipase Regulation

Lipoprotein Lipase: Biosynthesis, Regulatory Factors, and Its Role in Atherosclerosis and Other Diseases.

Structure of the lipoprotein lipase–GPIHBP1 complex that mediates plasma triglyceride hydrolysis

New Insights in Regulation Factors of Lipoprotein Lipase

Lipoprotein Lipase: from Gene to Atherosclerosis.

Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies

The biogenesis and transport of triglyceride-rich lipoproteins

A Compound Heterozygous Mutation of Lipase Maturation Factor 1 is Responsible for Hypertriglyceridemia of a Patient

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Current Progress in Lipoprotein Lipase and Atherosclerosis

Severe hypertriglyceridemia caused by Gpihbp1 deficiency facilitates vascular remodeling through increasing endothelial activation and oxidative stress

A unified model for regulating lipoprotein lipase activity

Pla2g12b drives expansion of triglyceride-rich lipoproteins

Adipose Triglyceride Lipase in Hepatic Physiology and Pathophysiology

Abstract 330: Liver-Specific Phospholipids Transfer Protein Activity Has Significant Contribution in Hepatocyte Apob-Containing Lipoprotein Production and in Plasma Lipoprotein Metabolism

Lipoprotein Lipase and Its Regulators: an Unfolding Story.

The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis